37693-15-5 Usage
Description
2,6-Dichloro-4-nitro-m-cresol is an organic compound characterized by the presence of two chlorine atoms at the 2nd and 6th positions, a nitro group at the 4th position, and a methyl group at the 3rd position on a methylphenol (cresol) structure. This chemical serves as an important intermediate in the synthesis of various organic compounds and has potential applications in biological studies.
Uses
Used in Chemical Synthesis:
2,6-Dichloro-4-nitro-m-cresol is used as an intermediate in the synthesis of 3,5-Dichloro-2-methyl-benzoquinone (D435355), a compound that has potential applications in various chemical processes.
Used in Biological Studies:
In the field of biological research, 3,5-Dichloro-2-methyl-benzoquinone, synthesized using 2,6-Dichloro-4-nitro-m-cresol, is utilized to evaluate the cytotoxicity and oxidative damage induced by halobenzoquinones. Specifically, it is employed to study the effects on T24 bladder cancer cells, providing insights into the potential therapeutic applications and mechanisms of action against cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 37693-15-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,6,9 and 3 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 37693-15:
(7*3)+(6*7)+(5*6)+(4*9)+(3*3)+(2*1)+(1*5)=145
145 % 10 = 5
So 37693-15-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H5Cl2NO3/c1-3-5(10(12)13)2-4(8)7(11)6(3)9/h2,11H,1H3
37693-15-5Relevant articles and documents
MODULATORS OF THR-β AND METHODS OF USE THEREOF
-
Paragraph 00406, (2020/11/23)
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IlIa, lIIb, IlIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF
-
Paragraph 00298, (2020/01/08)
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.